PE20030239A1 - Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales - Google Patents

Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales

Info

Publication number
PE20030239A1
PE20030239A1 PE2002000592A PE2002000592A PE20030239A1 PE 20030239 A1 PE20030239 A1 PE 20030239A1 PE 2002000592 A PE2002000592 A PE 2002000592A PE 2002000592 A PE2002000592 A PE 2002000592A PE 20030239 A1 PE20030239 A1 PE 20030239A1
Authority
PE
Peru
Prior art keywords
mycoplasma bovis
vaccine
animals
methods
bovis
Prior art date
Application number
PE2002000592A
Other languages
English (en)
Inventor
Robin Lee Keich
David Ross Mcgavin
Robert John Yancey
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030239A1 publication Critical patent/PE20030239A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA FORMULACION DE VACUNA PARA LA INMUNIZACION DE UN ANIMAL QUE COMPRENDE UNA CANTIDAD EFECTIVA INMUNOLOGICAMENTE DE CELULAS INACTIVADAS DE MYCOPLASMA BOVIS COMPLETAS O PARCIALES, UN VEHICULO ACEPTABLE, UN COADYUVANTE. LA FORMULACION CONTIENE LA CANTIDAD EFECTIVA DE VACUNA DE M. BOVIS DE 1x10 6 A 5X10 10 UNIDADES FORMADORAS DE COLONIA (ufc) POR DOSIS. LA VACUNA DE MYCOPLASMA BOVIS COMPRENDE ADEMAS ANTIGENOS DE UN PATOGENO VIRAL O BACTERIANO RESPIRATORIO, INTESTINAL O REPRODUCTIVO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DE VACUNA DE MYCOPLASMA BOVIS QUE COMPRENDE HACER CRECER UN AISLADO DEL MISMO EN CULTIVO O UN MEDIO ADECUADO, TRATAL EL CULTIVO CON UNA ETILENIMINA BINARIA PARA INACTIVAR EL MYCOPLASMA BOVIS Y MEZCLAR EL MYCOPLASMA BOVIS INACTIVADO CON UN VEHICULO ADECUADO
PE2002000592A 2001-07-02 2002-07-01 Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales PE20030239A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30263801P 2001-07-02 2001-07-02

Publications (1)

Publication Number Publication Date
PE20030239A1 true PE20030239A1 (es) 2003-03-21

Family

ID=23168600

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000592A PE20030239A1 (es) 2001-07-02 2002-07-01 Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales

Country Status (31)

Country Link
US (1) US20030147914A1 (es)
EP (1) EP1401488A1 (es)
JP (1) JP2004536106A (es)
KR (1) KR20040030783A (es)
CN (1) CN1522152A (es)
AP (1) AP2002002568A0 (es)
AR (1) AR036125A1 (es)
BG (1) BG108496A (es)
BR (1) BR0210798A (es)
CA (1) CA2452580A1 (es)
CZ (1) CZ20033465A3 (es)
EA (1) EA200301324A1 (es)
GT (1) GT200200139A (es)
HN (1) HN2002000162A (es)
HR (1) HRP20031078A2 (es)
HU (1) HUP0501188A2 (es)
IL (1) IL159516A0 (es)
IS (1) IS7078A (es)
MA (1) MA27048A1 (es)
MX (1) MXPA03011815A (es)
NO (1) NO20035767L (es)
OA (1) OA12640A (es)
PA (1) PA8549801A1 (es)
PE (1) PE20030239A1 (es)
PL (1) PL373891A1 (es)
SK (1) SK15802003A3 (es)
TN (1) TNSN03154A1 (es)
UY (1) UY27365A1 (es)
WO (1) WO2003004052A1 (es)
YU (1) YU102103A (es)
ZA (1) ZA200309747B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179473B2 (en) 1998-06-05 2007-02-20 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
US7135561B2 (en) 2001-09-06 2006-11-14 Boehringer Ingelheim Vetmedica Gmbh Infectious bovine viral diarrhea virus clone
US7279166B2 (en) * 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
SE0301436D0 (sv) * 2003-05-16 2003-05-16 Joakim Westberg New proteins
US7572455B2 (en) * 2004-05-19 2009-08-11 Boehringer Ingelheim Vetmedica Gmbh Vaccine comprising an attenuated pestivirus
US20090068223A1 (en) * 2005-11-15 2009-03-12 Boehringer Ingelheim Vetmedica, Inc. Combination vaccine comprising an attenuated bovine viral diarrhea virus
US20110059437A1 (en) * 2006-09-07 2011-03-10 Boehringer Ingelheim Vetmedica, Inc. Pcr-based genotyping
AU2007297287B2 (en) 2006-09-11 2013-03-14 Zoetis Services Llc Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
UY31437A1 (es) * 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
UY31930A (es) * 2008-06-25 2010-01-29 Boheringer Ingelheim Pharma Kg Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante
NZ589981A (en) * 2008-07-03 2012-11-30 Univ Iowa State Res Found Inc Cattle vaccines comprising a disrupted M. bovis bacterium
CN102202685A (zh) * 2008-10-31 2011-09-28 贝林格尔.英格海姆维特梅迪卡有限公司 包含来自牛枝原体的抗原的多种抗原在多价疫苗组合物中的用途
US8846054B2 (en) * 2009-01-09 2014-09-30 Boehringer Ingelheim Vetmedica, Inc. Method of treating pregnant cows and/or heifers
UY32570A (es) * 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
US9539209B2 (en) 2009-06-04 2017-01-10 National Institute Of Infectious Diseases Vaccine for mycoplasma infection
CN102220263B (zh) * 2011-05-06 2012-10-03 华中农业大学 一种牛支原体致弱菌株及其应用
BR112015012711B1 (pt) 2012-12-28 2022-08-16 Boehringer Ingelheim Vetmedica Gmbh Método para preparar uma composição imunogênica para o tratamento e/ou a profilaxia de infecções por mycoplasma
CN104857509A (zh) * 2015-06-02 2015-08-26 福清市默克兽医院 牛支原体肺炎组织灭活疫苗的制备方法、配方及使用方法
CN108135989B (zh) 2015-08-14 2022-08-09 硕腾服务有限责任公司 牛支原体组合物
CN105441368B (zh) * 2016-01-19 2019-01-01 福清市默克兽医院 一株牛支原体及其应用
CN106929452B (zh) * 2017-04-11 2020-06-12 河南省农业科学院畜牧兽医研究所 一株牛支原体及其应用
CN109022314B (zh) * 2018-08-06 2021-08-13 北京华夏兴洋生物科技有限公司 一株牛支原体及其在疫苗研制中的应用
CN110338138B (zh) * 2019-06-19 2021-04-06 山东省农业科学院奶牛研究中心 一种牛支原体感染豚鼠的动物模型构建方法及其应用
CN112301041B (zh) * 2020-10-09 2022-05-24 华中农业大学 牛支原体p21蛋白及其应用
CN113546162B (zh) * 2021-05-31 2023-07-18 江苏省农业科学院 一种支原体疫苗及其制备方法
CN113604492B (zh) * 2021-09-10 2023-07-07 苏州世诺生物技术有限公司 融合基因、融合蛋白及制备方法和牛支原体亚单位疫苗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
JP2003513935A (ja) * 1999-11-08 2003-04-15 バイオミューン マイコプラズマ・ボビスに対するワクチンおよび使用方法
DE29921392U1 (de) * 1999-12-06 2000-03-16 Dr. Felgenträger & Co. Öko-Chem. und Pharma GmbH, 06862 Rodleben Mykoplasma-bovis-Kombinations-Vakzine für Rinder
US6548069B2 (en) * 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin

Also Published As

Publication number Publication date
KR20040030783A (ko) 2004-04-09
PL373891A1 (en) 2005-09-19
WO2003004052A1 (en) 2003-01-16
BG108496A (en) 2005-02-28
CN1522152A (zh) 2004-08-18
MXPA03011815A (es) 2004-04-02
GT200200139A (es) 2003-02-13
IS7078A (is) 2003-12-15
HRP20031078A2 (en) 2005-08-31
UY27365A1 (es) 2003-04-30
NO20035767L (no) 2004-01-30
PA8549801A1 (es) 2003-09-17
CZ20033465A3 (cs) 2004-12-15
ZA200309747B (en) 2005-05-27
JP2004536106A (ja) 2004-12-02
EP1401488A1 (en) 2004-03-31
HUP0501188A2 (en) 2006-05-29
CA2452580A1 (en) 2003-01-16
BR0210798A (pt) 2006-05-23
SK15802003A3 (sk) 2005-01-03
HN2002000162A (es) 2002-09-17
MA27048A1 (fr) 2004-12-20
TNSN03154A1 (fr) 2005-12-23
OA12640A (en) 2006-06-15
IL159516A0 (en) 2004-06-01
US20030147914A1 (en) 2003-08-07
EA200301324A1 (ru) 2004-12-30
YU102103A (sh) 2006-05-25
AP2002002568A0 (en) 2002-06-30
AR036125A1 (es) 2004-08-11

Similar Documents

Publication Publication Date Title
PE20030239A1 (es) Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales
Jalava et al. Bacterial ghosts as vaccine candidates for veterinary applications
Glisson Bacterial respiratory disease of poultry
JP2004536106A5 (es)
US20210030862A1 (en) A vaccine for protection against streptococcus suis
KR101818901B1 (ko) 돼지흉막폐렴균의 재조합 ApxIA, ApxIIA, ApxIIIA toxin의 N 또는 C 말단 분자 및 불활화 돼지흉막폐렴균을 이용한 돼지 흉막폐렴 백신 조성물
Clausse et al. Evaluation of the efficacy of outer membrane protein 31 vaccine formulations for protection against Brucella canis in BALB/c mice
US11696944B2 (en) Vaccine for protection against Streptococcus suis
PE72699A1 (es) Antigeno del rotavirus, vacuna y agente diagnostico para infeccion por rotavirus y un metodo para producir el antigeno
JP2010510197A (ja) ワクチンの製造のためのクロストリジウム・パーフリンジェンスｃ型細菌の使用
MX2011001910A (es) Composicion inmunologica.
Söderlind et al. Effect of parenteral vaccination of dams on intestinal Escherichia coli in piglets with diarrhea
Abd El Fadeel et al. Preparation and efficacy of freeze-dried inactivated vaccine against bovine viral diarrhea virus genotypes 1 and 2, bovine herpes virus type 1.1, bovine parainfluenza-3 virus, and bovine respiratory syncytial virus
Sarwar et al. Factors Affecting Potency of Hemorrhagic Septicemia Vaccines
AR009650A1 (es) Mycoplasma synoviae atenuado vivo, su uso, un cultivo microbiologico que lo comprende, una vacuna bacteriana atenuada viva para la proteccion de las aves de corral contra la infeccion por mycoplasma synoviae y un metodo para preparar dicha vacuna.
Pieters et al. When is the best time to vaccinate piglets against Mycoplasma hyopneumoniae
RU2462263C2 (ru) Применение бактерии clostridium perfringens типа с для производства вакцины
I EL-Hawary et al. Immunological response of locally prepared oil adjuvanted pneumo-5 vaccine in calves
Huberman et al. Evaluation of the protection conferred by a disinfectant against clinical disease caused by Avibacterium paragallinarum serovars A, B, and C from Argentina
Mandado The current status of veterinary vaccinology: A review
US20210393696A1 (en) Compositions for improving vaccine safety and efficacy and methods of use thereof
Royan Comparison of the BVDV, BHV-1, and BRSV anamnestic response to modified-live or inactivated vaccines in calves previously vaccinated with a modified-live virus vaccine.
El-Bagoury et al. Comparative evaluation of different inactivated Rift valley fever virus vaccine adjuvanted with montanide oil ISA 61 VG, montanide oil ISA 201 VG, and aluminum hydroxide gel
Chagas et al. Recombinant Live-Attenuated Salmonella Vaccine for Veterinary Use
Maass et al. Impact of PCV2 viremia in vaccinated and non-vaccinated pigs

Legal Events

Date Code Title Description
FC Refusal